--- title: "Dow 30 Earnings: Pfizer Fourth Quarter 2016" description: dow 30 earnings, pfizer, attractive core holding large pharma space, adjusted earnings $2.50 -$2.60 share revenues $52 billion-$54 billion, oncology key driver image: https://investor.valueline.com/hubfs/VL%20Blog%20Images/iStock-463594335.jpg --- [![The Value Line Blog](https://investor.valueline.com/hubfs/VL%20Blog%20Images/vl_blog_header.png)](https://investor.valueline.com/blog) [Stock Highlights](https://investor.valueline.com/blog/topic/stock-highlights) # Dow 30 Earnings: Pfizer Fourth Quarter 2016 January 31, 2017 New York-based drugmaker and Dow-30 component **Pfizer** ([PFE](https://research.valueline.com/secure/research#sym=PFE&list=dow30&sec=company) - [Free Pfizer Stock Report](https://research.valueline.com/secure/api/report?documentID=2185-VL_20170106_VLIS_PFE_4373_01-246ITD8505241BT6DEVFB2P3GB&symbol=PFE))has reported fourth-quarter earnings of $0.13 a share, versus a loss of $0.03 a share in the comparable period of 2015. The year-over-year increase in profits was driven primarily by reduced spending on production (-6%) and SG&A (-12%), partially offset by higher R&D costs (+7%) and lower revenues (-3%). Meanwhile, adjusted earnings, which exclude one-time gains, charges, and other nonrecurring items, and are more closely followed by Wall Street, came in at $0.47 a share, versus $0.53 in 2015. The adjusted tally missed consensus expectations of $0.50, despite revenues being relatively in line. All told, Pfizer concluded full-year 2016 with GAAP earnings of $1.17 a share, up from $1.11 in 2015, and adjusted earnings of $2.40 a share, up from $2.20 in 2015. Shares of PFE rose modestly on the release. In the December period, total sales fell 3% year over year, to $13.6 billion, ending a streak of four consecutive quarters of top-line growth. Management noted that four fewer selling days in the U.S. and three in international markets compared to the fourth quarter of 2015 had a negative impact of roughly $750 million. On the operating front, the company's Innovative Health segment, which sells newer, patent-protected drugs, contributed sales of $7.7 billion (+1%), driven by continued growth of IBRANCE, primarily in the U.S., *ELIQUIS* globally, the addition of *XTANDI* revenues stemming from the Medivation acquisition in September, and strong growth in the *XELJANZ* (+61%) and *LYRICA* (+11%) franchises. Further gains were mitigated however by a steep decline in *PREVNAR* vaccine sales (-24%), which management attributed to demand softness for the adult indication, and continued fallout in *ENBREL* (-22%) due to biosimilar competition. Meanwhile, the company's Essential Health segment, which sells older, mostly off-patent drugs, saw its sales decline 8% year over year, to $5.9 billion. This resulted from a 21% dip in *Peri-LOE* Products and a 3% decrease in Legacy Established Products, partially offset by a 2% increase in the Sterile Injectable Pharmaceuticals segment. Following the Q4 report, management released 2017 guidance that seemed to be on par with what Wall Street was anticipating. The company expects adjusted earnings of $2.50-$2.60 a share on revenues of $52 billion-$54 billion, where analysts on average were targeting $2.56 a share on revenues of $54 billion. We expect Pfizer's fast-growing oncology business (sales +56% in 2016) will remain a key comp driver over the next several quarters, helping to offset generic pressures in some of its more mature franchises. We would not rule out the possibility of additional large-scale M&A activity as well, given the company's recent appetite. Pfizer acquired Hospira for $15 billion in September, 2015, Anacor Pharmaceuticals for $5 billion in June, 2016, and Medivation for $14 billion in September, 2016. All told, we continue to view Pfizer as an attractive core holding within the large pharma space. The company has strong finances, high-grade fundamentals, and an impressive track record. An above-average dividend yield and expectations for continued stock repurchases should enhance shareholder value. The blue ship stock holds our Highest rank for Safety (1). The company's Financial Strength is also top notch (A++). **About The Company:**[Pfizer](http://www.valueline.com/WorkArea/linkit.aspx?LinkIdentifier=id&ItemID=9375) is a major producer of pharmaceuticals. The company is engaged in discovering, developing, and manufacturing of healthcare products. Important product names include *LYRICA* (nerve and muscle pain); *PREVNAR* (vaccine); ENBREL (arthritis, psoriasis, and more); *IBRANCE* (advanced breast cancer) and *CELEBREX* (osteoarthritis, rheumatoid arthritis). The company acquired injectable drugmaker Hospira in 2015 and medical devices producer Medivation in 2016. *At the time of this article’s writing, the author did not have positions in any of the companies mentioned.* [![Register now for our free One Stock to Buy webinar](https://no-cache.hubspot.com/cta/default/2532383/5a80130b-f0ce-4bd8-acbd-f077f2232ec5.png)](https://cta-redirect.hubspot.com/cta/redirect/2532383/5a80130b-f0ce-4bd8-acbd-f077f2232ec5) ### Popular Posts Search Search Blog ### Topics - [Investing 101 (2)](https://investor.valueline.com/blog/topic/investing-101) - [Market Commentary (37)](https://investor.valueline.com/blog/topic/market-commentary) - [Stock Highlights (390)](https://investor.valueline.com/blog/topic/stock-highlights) - [Stock Market Today (2071)](https://investor.valueline.com/blog/topic/stock-market-today) Copyright 2026 Value Line, Inc. All Rights Reserved. Factual material is obtained from sources believed to be reliable and is provided without warranties of any kind. VALUE LINE IS NOT RESPONSIBLE FOR ANY ERRORS OR OMISSIONS HEREIN OR ANY DAMAGES OR LOSSES ARISING FROM ANY USE OF THE INFORMATION CONTAINED HEREIN. This blog is strictly for subscriber's own, non-commercial, internal use. No part of it may be reproduced, stored or transmitted in any printed, electronic or other form, or used for generating or marketing any printed or electronic publication, service or product. Officers, directors, or employees of Value Line, Inc. and its affiliates and subsidiaries, and EULAV Asset Management, may own stocks that are featured in this email. Nothing herein should be construed as an offer to buy or sell securities or to give individual investment advice. Value Line, the Value Line logo, The Most Trusted Name in Investment Research, “Smart research. Smarter investing.”, The Value Line Investment Survey, Timeliness, and Safety are trademarks or registered trademarks of Value Line, Inc. and/or its affiliates in the United States and other countries.